The Bactrian approach

Ablynx N.V. is beginning to disclose preclinical data showing that its nanobodies may have advantages in terms of design and mechanism over conventional antibodies.

The company's nanobodies are based on small fragments of naturally occurring single-domain antibodies from the camelid family, and are only one-tenth the size of conventional antibodies(see BioCentury, April 12). Ablynx's first three programs are

Read the full 574 word article

How to gain access

Continue reading with a
two-week free trial.